Regeneron Pharmaceuticals, Inc.REGN

Regeneron Pharmaceuticals, Inc. (REGN) has a therapeutic focus in oncology. The company's oncology portfolio includes LIBTAYO (cemiplimab-rwlc), which has been associated with various immune-mediated adverse reactions. For instance, Grade 3 immune-mediated dermatologic adverse reactions occurred at an incidence of 1.0% with LIBTAYO (cemiplimab-rwlc), while Grade 2 immune-mediated pneumonitis incidence was 1.9% with LIBTAYO (cemiplimab-rwlc). Other notable adverse reactions include Grade 4 immune-mediated hepatitis at 0.2% incidence and Grade 3 hypophysitis at 0.2% incidence with LIBTAYO (cemiplimab-rwlc).

Another oncology drug, linvoseltamab (REGN5458), is being studied. In Study 1826, 72.6% of all 200 mg patients experienced Grade 3 or 4 TEAEs, and 12.0% experienced Grade 5 TEAEs. Grade 3 or 4 infections were observed in 36% of patients, and Grade ≥3 neutropenia occurred in 40.2% of patients. The median time to not getting grade ≥3 infection for linvoseltamab (REGN5458) ranged from 15 weeks (Q1 CMAXWKE) to >176 weeks (Q4 CMAXWKE).